Chemotactic cytokines mediate leukocyte recruitment in fibrotic lung disease

NeuroSignals

Volumn 5, Issue 4, 1996, Pages 223-231

  Smith, Robert E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bleomycin; CBA J mice; Fibrosis; Lymphocytes; Macrophage inflammatory protein 1; Macrophages; Monocyte chemoattractant protein 1; Neutrophils

Indexed keywords

BLEOMYCIN; CHEMOKINE; COLLAGEN; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; FIBROBLAST; IMMUNOTHERAPY; LEUKOCYTE ACTIVATION; LUNG FIBROSIS; LYMPHOCYTE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA;

ANIMALS; ANTIBODIES; ANTIGENS, SURFACE; BLEOMYCIN; CHEMOKINE CCL2; FLOW CYTOMETRY; HUMANS; IMMUNIZATION, PASSIVE; LEUKOCYTES; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; MICE, INBRED CBA; PULMONARY FIBROSIS;

ANIMALIA; RODENTIA;

EID: 0029790933     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000109194     Document Type: Article

References (36)

1. Schrier DJ, Kunkel RG, Phan SH: The role of strain variation in murine bleomycin-induced pulmonary fibrosis, Am Rev Respir Dis 1983; 127:63-66.
2. Adamson IY, Bowden DH: The pathogenesis of bleomycin-induced pulmonary fibrosis in mice, Am J Pathol 1974;77:185-197.
3. Aso Y, Yoneda Y: Morphological and biochemical study of pulmonary changes induced by bleomycin in mice, Lab Invest 1976;35:558-568.
4. Bcdrossian CMW, Grcnnberg SD, Yawn DH, O’Neal RM: Experimentally induced bleomycin sulfate pulmonary toxicity, Arch Pathol Lab Med 1977;101:248-254.
5. Chandler DB: Possible mechanism of bleomycin-induced fibrosis, Clin Chest Med 1990;11:21-30.
6. Bowden DH: Unraveling pulmonary fibrosis: The bleomycin model, Lab Invest 1984;50:487-488.
7. Chandler DB, Hyde DM, Giri SN: Morphometrie estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters, Am J Pathol 1983;112:170-177.
8. Smith RE, Strieter RM, Phan SH, Lukács NW, Huffnagle GB, Wilke CA, Burdick MD, Lincoln P, Eva-noff H, Kunkel SL: Production and function of murine macrophage inflammatory protein-la in bleomycin-induced lung injury, J Immunol 1994;153:4704-4712.
9. Thrall RS, Barton RW, D’Amato DA, Sulavik SB: Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induccd pulmonary fibrosis in the rat, Am Rev Respir Dis 1982; 126: 488-492.
10. Piguct PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis, J Exp Med 1989;170:655-663.
11. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA: Bleomycin-induced pulmonary fibrosis in the rat, Am J Pathol 1979; 95:117-130.
12. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH: Lung monocyte chcmoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis, J Immunol 1994;153:4733-4741.
13. Mori H, Kawada K, Zhang P, Uesu-gi Y, Sakamato O, Koda A: Bleomycin-induced pulmonary fibrosis in genetically mast-cell-deficient WBB6F1-W/W mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis, Int Arch Allergy Appl Immunol 1991;95:195-201.
14. Thrall RS, Phan SH, McCormick JR, Ward PA: The development of bleomycin-induced pulmonary fibrosis in neutrophil-depleted and complement-depleted rats, Am J Pathol 1981;105:76-81.
15. Giri SN, Witt TC: Effects of intratracheal administration of bleomycin on prostaglandins and throm-boxane-B2 and collagen levels of the lung in hamsters, Exp Lung Res 1985;9:119-133.
16. Micallef M, Hosokawa M, Togashi Y, Kobayashi H: Rat macrophage activation after treatment with the bleomycin group of antitumour antibiotics in vivo, Cancer Immunol Immunother 1992;35:106-112.
17. Thrall RS, Barton RW: Comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis, Am Rev Respir Dis 1984;129:279-283.
18. Strieter RM, Kunkel SL: The immu-nopathology of chemotactic cytokines; in Westwick J, Lindley IJD, Kunkel SL (eds): Chcmokines, New York, Plenum Press, 1993. pp 19-28.
19. Oppenheim JJ, Zachariae CO, Mukaida N, Matsusshima K: Properties of the novel proinfiammatory super-gene ‘intercrine’ cytokine family, Annu Rev Immunol 1991;9:617-648.
20. Fahey TJ III, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, Cerami A, Sherry B: Macrophage inflammatory protein 1 modulates macrophage function, J Immunol 1992;148:2764-2769.
21. Jiang Y, Bellcr DI, Frendl G, Graves DT: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes, J Immunol 1992;148:2423-2428.
22. Standiford TJ, Kunkel SL, Lukács NW, Greenberger MJ, Danforth JM, Kunkel RG, Strieter RM: Macrophage inflammatory protein-la mediates lung leukocyte recruitment, lung injury, and early mortality in murine endotoxemia, J Immunol, submitted.
23. Zhou Z, Kim Y, Pollok K, Hurtado J, Lee J, Broxmeyer HE, Kwon BS: Macrophage inflammatory protcin-la rapidly modulates its receptors and inhibits the anti-CD-3-me-diated proliferation of T lymphocytes, J Immunol 1993; 151:4333-4341.
24. Lukács NW, Chensue SW, Smith RE, Strieter RM, Warmington K, Wilke C, Kunkel SL: Production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-la by inflammatory granuloma fibroblasts, Am J Pathol 1994; 144:711-718.
25. Standiford TJ, Kunkel SL, Liebler JM, Burdick MD, Gilbert AR, Strieter RM: Gene expression of macrophage inflammatory protein-la from human blood monocytes and alveolar macrophages is inhibited by interleukin-4. Am J Respir Cell Mol Biol 1993;9:192-198.
26. Davatclis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Gallegos C, Coit D, Merrywcathcr J, Cerami A: Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chcmokine properties, J Exp Med 1988;167:1939-1944.
27. Alam R, Forsythe PA, Stafford S, Lett-Brown MA, Grant JA: Macrophage inflammatory protein-1 alpha activates basophils and mast cells, J Exp Med 1992;176:781-786.
28. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ: Preferential migration of activated CD4+ and CD8+ T cells in response to M1P-1 alpha and MIP-1 beta, Science 1993;260:355-358.
29. Schall TJ, Bacon K, Camp RD, Kas-pari JW, Goeddel DV: Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta attract distinct populations of lymphocytes, J Exp Med 1993; 177: 1821-1826.
30. Rot A, Krieger M, Brunner T, Bi-schoff SC, Schall TJ, Dahinden CA: RANTES and macrophage inflammatory protein- la induce the migration and activation of normal human eosinophil granulocytes, J Exp Med 1992;176:1489-1495.
31. Kristensen MS, Dclcuran BW, Larsen CG, Thcstrup-Pcdersen K, Palu-dan K: Expression of monocyte chc-motactic and activating factor (MCAF) in skin related cells, A comparative study, Cytokine 1993;5: 520-524.
32. Alam R, Kumar D, Anderson-Wal-tcrs D, Forsythe PA: Macrophage inflammatory protein-1 a and monocyte chemoattractant peptide-1 elicit immediate and late cutaneous reactions and activate murine mast cells in vivo, J Immunol 1994:152: 1298-1303.
33. Dipietro LA, Polverini PJ, Rahbc SM, Kovacs EJ: Modulation of JE/ MCP-1 expression in dermal wound repair, Am J Pathol 1995; 146:868-875.
34. Standiford TJ, Rolfe MW, Kunkel SL, Lynch JP III, Burdick MD, Gilbert AR, Orringcr MB, Whyte RI, Strieter RM: Macrophage inflammatory protein-la expression in interstitial lung disease, J Immunol 1993;151:2852-2863.
35. Calabresi P, Parks RE Jr: Chemotherapy of neoplastic diseases; in Gilman AG, Goodman LS, Gilman A (eds): Goodmans and Gilmans Pharmacological Basis of Therapeutics, Philadelphia, Lippincott, 1980. pp 1256-1258.
36. Coffman B: Surface antigen expression and immunoglobin rearrangement during mouse pre-B cell development, Immunol Rev 1982:69:5-23.